前列腺癌查可以降低75-79岁男性的死亡率吗? 一个针对目标试验模拟的协议
Ahmad Abbadi1, Chiara Micoli1, Andrea Discacciati1
1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden.
European urology open science
|November 24, 2025
概括
这项研究调查了75-79岁男性的前列腺特异性抗原 (PSA) 查. 它旨在确定PSA测试在这个年龄组是否提供生存益处,并减少死亡率,而不会增加过度诊断.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 在瘤学瘤学.
- 流行病学 流行病学
背景情况:
- 机会性前列腺特异性抗原 (PSA) 测试在75-79岁的男性中很常见.
- 目前的指导方针建议对预期寿命≥10岁的男性进行PSA查,之前的年龄值为70-74岁.
- 75-79岁的瑞典男性现在平均预期寿命超过10年,需要更新查考虑.
研究的目的:
- 评估基于PSA的查对75-79岁的男性没有先前前列腺癌诊断的生存益处.
- 评估PSA查对所有原因和前列腺癌特异性死亡率对这一人口群体的影响.
- 为可能将前列腺癌查指南扩展到老年男性提供证据.
主要方法:
- 使用斯德哥尔摩前列腺癌诊断注册 (2007-2023) 进行目标试验仿真研究.
- 采用序列和克隆-传感器-重量仿真与基于PSA测试记录的意图到屏幕分析.
- 使用生存模型和累积发病率函数 (CIF) 分析生存结果,并对随访持续时间和入学标准进行敏感性分析.
主要成果:
- 这项研究旨在确定75-79岁男性PSA查是否会导致死亡率降低.
- 它将量化查对所有原因和前列腺癌特异性死亡率的影响.
- 结果将在不同的随访期和入学标准中进行比较.
结论:
- 这项研究旨在确定PSA查是否为75-79岁的男性提供生存优势.
- 研究结果将为有关老年人群前列腺癌查的临床建议提供信息.
- 这项研究将有助于澄清降低死亡率与此年龄组过度诊断风险之间的平衡.
相关概念视频
01:20Disorders of the Male Reproductive System
3.9K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
3.9K
01:21Cancer Survival Analysis
633
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
633